Nisoldipine
From Wikipedia, the free encyclopedia
Nisoldipine
|
|
Systematic (IUPAC) name | |
methyl2- methylpropyl2,6-dimethyl-4-(2-nitrophenyl)- 1,4-dihydropyridine-3,5-dicarboxylate | |
Identifiers | |
CAS number | |
ATC code | C08 |
PubChem | |
DrugBank | |
Chemical data | |
Formula | C20H24N2O6 |
Mol. mass | 388.414 g/mol |
Pharmacokinetic data | |
Bioavailability | ? |
Protein binding | 99% |
Metabolism | ? |
Half life | 7-12 hours |
Excretion | ? |
Therapeutic considerations | |
Pregnancy cat. |
C(US) |
Legal status | |
Routes | Oral |
Nisoldipine (INN) is a calcium channel blocker of the dihydropyridine class. It sold in the United States under the proprietary name Sular.
[edit] External links
- DDB 30009
- Mielcarek J, Grobelny P, Szamburska O (2005). "The effect of beta-carotene on the photostability of nisoldipine.". Methods Find Exp Clin Pharmacol 27 (3): 167–71. doi: . PMID 15834448.
- Missan S, Zhabyeyev P, Dyachok O, Jones S, McDonald T (2003). "Block of cardiac delayed-rectifier and inward-rectifier K+ currents by nisoldipine.". Br J Pharmacol 140 (5): 863–70. doi: . PMID 14530219.
- Hamilton S, Houle L, Thadani U. "Rapid-release and coat-core formulations of nisoldipine in treatment of hypertension, angina, and heart failure.". Heart Dis 1 (5): 279–88. PMID 11720635.
|